Table 3.

Patients’ vaccine, treatment regimens and outcomes.

	Vaccinated patients (n = 82)	Control group (n = 82)	p-value
Duration of hospitalization (days)	8 (5–12)	11 (7–21)	<0.001
Follow-up after COVID-19	57 (32–81)	134 (104–203)	0.812
Vaccine Regimens
Two doses of CoronoVac	21 (25.6)
Two doses of BNT162b2	20 (24.4)
Three doses of CoronoVac	14 (17.1)
Two doses of CoronoVac and one of BNT162b2	27 (32.9)
Withdrawal of IS agent
Calcineurin inhibitors	9 (11)	10 (12.2)	0.807
Antimetabolites	66 (80.5)	69 (84.1)	0.539
Treatment of infection
Hydroxychloroquine	0	17 (20.7)	<0.001
Favipiravir	60 (73.1)	64 (78)	0.467
Cytokine‐targeted therapy	4 (4.9)	6 (7.3)	0.514
Anakinra	3 (3.7)	4 (4.9)	0.699
Tocilizumab	1 (1.2)	2 (2.4)	0.560
Anticoagulation	17 (20.7)	34 (41.5)	0.004
Antibiotics	18 (22.5)	38 (46.3)	<0.001
Ventilation devices
Nasal cannula	9 (11)	20 (24.3)	0.244
Non-invasive ventilation	4 (4.9)	8 (9.8)	0.230
Mechanical ventilation	5 (6.1)	10 (12.2)	0.168
Acute kidney injury	13 (15.9)	20 (24.4)	0.160
Stage 1	9 (11)	7 (8.8)	0.599
Stage 2	3 (3.7)	6 (7.3)	0.495
Stage 3	1 (1.2)	7 (8.5)	0.029
Endpoints
Cytokine storm	4 (4.9)	11 (13.4)	0.061
ARDS	5 (6.1)	10 (12.2)	0.168
Hospitalized patient	17 (20.7)	34 (41.5)	0.004
Follow-up in ICU	5 (6.1)	10 (12.2)	0.168
Death	4 (4.9)	9 (11)	0.247

Abbreviations; IS: immunosuppression; IVIG: intravenous immunoglobulin; ARDS: acute respiratory distress syndrome; ICU: intensive care unit.

P-values compared vaccinated patients and control group obtained from the Chi-Square test, Fisher’s exact test, or Mann–Whitney U test. Data were presented as n (%) or median [Interquartile range 25–75] unless otherwise noted. Bold indicates statistically significant associations (p < 0.05).